Evidence map›Paper›PMID 33119627›Full record

ArticlePloS one2020

Trends in de-lousing of Norwegian farmed salmon from 2000-2019-Consumption of medicines, salmon louse resistance and non-medicinal control methods.

Elena Myhre Jensen, Tor Einar Horsberg, Sigmund Sevatdal, Kari Olli Helgesen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Hepatic melanomacrophage centers in the arctic cultured fishAquaculture (Amsterdam, Netherlands) · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Elena Myhre JensenFaculty of Veterinary Medicine, Sea Lice Research Center, Norwegian University of Life Sciences (NMBU), Oslo, Norway.ORCID 0000-0003-0259-0916
Tor Einar HorsbergFaculty of Veterinary Medicine, Sea Lice Research Center, Norwegian University of Life Sciences (NMBU), Oslo, Norway.
Sigmund SevatdalVESO Vikan, Namsos, Norway.
Kari Olli HelgesenNorwegian Veterinary Institute, Oslo, Norway.
Norwegian University of Life Sciences · NONorwegian Veterinary Centre for Contract Research and Commercial Services · NONorwegian Veterinary Institute · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The salmon louse Lepeophtheirus salmonis has been a substantial obstacle in Norwegian farming of Atlantic salmon for decades. With a limited selection of available medicines and frequent delousing treatments, resistance has emerged among salmon lice. Surveillance of salmon louse sensitivity has been in place since 2013, and consumption of medicines has been recorded since the early 80's. The peak year for salmon lice treatments was 2015, when 5.7 times as many tonnes of salmonids were treated compared to harvested. In recent years, non-medicinal methods of delousing farmed fish have been introduced to the industry. By utilizing data on the annual consumption of medicines, annual frequency of medicinal and non-medicinal treatments, the aim of the current study was to describe the causative factors behind salmon lice sensitivity in the years 2000-2019, measured through toxicity tests-bioassays. The sensitivity data from 2000-2012 demonstrate the early emergence of resistance in salmon lice along the Norwegian coast. Reduced sensitivity towards azamethiphos, deltamethrin and emamectin benzoate was evident from 2009, 2009 and 2007, respectively. The annual variation in medicine consumption and frequency of medicinal treatments correlated well with the evolution in salmon louse sensitivity. The patterns are similar, with a relatively small response delay from the decline in the consumption of medicines in Norway (2016 and onward) to the decline in measured resistance among salmon louse (2017 and onward). 2017 was the first year in which non-medicinal treatments outnumbered medicinal delousing treatments as well as the peak year in numbers of cleanerfish deployed. This study highlights the significance of avoiding heavy reliance on a few substance groups to combat ectoparasites, this can be a potent catalyst for resistance evolution. Further, it demonstrates the importance of transparency in the global industry, which enables the industry to learn from poor choices in the past.

Indexed as

AnimalsAntiparasitic AgentsAquacultureDrug ResistanceFish DiseasesFisheriesHumansNorwayOrganothiophosphatesPhthirapteraSalmo salarSeafoodAntiparasitic AgentsazamethiphosOrganothiophosphates

Identifiers

PMID33119627
PMCPMC7595418
OpenAlexW3094891738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.